Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lets not start throwing number around like that.
There is no doubt that there will have to be some kind of reverse split.
You did not think he was going to step down with out protecting himself. That's why i said last year with the moves he was making he was getting ready to step a side i just did not think it would have taken so long.
WIV since you are an investment banker let here your thoughts on this.
NEWS OUT:
Medizone International Announces Agreement Retaining EMA Partners as Advisor and Investment Bank
KALAMAZOO, MICH. March 1,2017 - Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, the only EPA cleared hospital room disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens, announced today that the Company has entered into a definitive agreement with EMA Partners retaining them as the Company's advisor for financing and investment banking matters.
In late 2016, AsepticSure was cleared by the U.S. Environmental Protection Agency for entry into the United States market. The Company has been preparing for entry into a significant market that has a growing need for effective technologies that are capable of breaking the hospital acquired infection cycle.
"We are very pleased to announce that Medizone International has reached an agreement to have EMA Partners serve as our advisor and investment bank. EMA Partners and its elite group of partners and life-science advisors have a remarkable track record of helping to create shareholder value in promising life-science companies," said David Esposito, Chairman and CEO of Medizone International. "As our team has completed several key milestones in the development of AsepticSure, we are preparing to scale our commercial operations in the United States and beyond. We look forward to EMA Partners helping us realize the full potential of our business."
"EMA Partners looks forward to working with the seasoned management team and board at Medizone to explore strategic options to scale the business and to develop strategic partnerships with a broad range of industry players," said Andy Raeder, founding partner of EMA Partners. "We believe the AsepticSure technology has the potential to significantly impact the large unmet need of reducing hospital acquired infections. In addition, we see a large number of other compelling areas where this technology could be deployed to increase value creation for the Company."
Medizone continues to execute on plans to increase manufacturing, technical service and support, and lead generation channels to secure initial U.S. customers for AsepticSure. The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.
About Medizone International, Inc.
Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 in response to the increased prevalence and awareness of hospital acquired infections. The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the Company released its AsepticSure system for use in Canada, and several other global markets. With EPA approval in late 2016, the Company is now prepared to expand into the U.S. market.
Safe Harbor Statement
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: j.pentony@medizoneint.com
For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com
About EMA Partners, LLC
EMA is focused on assisting its clients with mergers, acquisitions, divestitures, intellectual property licensing and sales, recapitalizations, transition planning and other transactional-based services.
We apply a process and perspective well suited to middle market clients across all geographies. With a professional staff of advisors from a variety of business disciplines, we are able to provide the strategy, analytics, marketing and transactional work to meet our clients' goals across industry verticals. This expertise is reflected in the wide range of transactions EMA has handled, ranging from outright sale of traditional industrial companies to licensing of sophisticated pre-revenue intellectual property.
Our focus has always been on the middle market, and on understanding client companies' objectives and strengths, communicating those strengths to prospective buyers or partners, and structuring transactions in a manner that maximizes value for our clients.
For more information, visit www.emapartners.com. Securities -related services provided through Burch & Company, Inc., member FINRA/SIPC.
MEDIZONE INTERNATIONAL INC. | 269-202-5020| www.medizoneint.com
Told you guys last year when he was getting thing arranged that he was stepping down. Post 41536
You do realize that would be 3 decimal point to the right to be sub penny 0.003
What did you expect to happen this week.
There are 189 followers on twitter for this company a good portion are health care related.
Depends on what we are talking about stocks or a product. If it is stocks then the 1 would have the same value as the 4 if it is product then the 1 gallon would be cheaper because buying in bulk you get a better price.
Before this company is sold there will have to be a reverse split something on the line of 1 for 500 or 1 for 1000. There is know way any company is going to buy it with this many shares out i,m 100% sure of this.
You need to watch the Bid and Ask if the Bid shares are at .12 with 20,000 available and the Ask is at .1498 with 50,000 available you can see what way they want it to go down and vice versa.
No i don't i think it is more that people were asking for news. I would love to see us at .25 to .50 by next year, but you don't want to just post any news then you get accused of pumping the stock. it's kind of catch 22 with small company that are just R & D type.
I don,t think that at all did you think this would move the stock .02 .03 .04 a share today ? It is news small but still an update of what is happening.
This would be a great question to ask at the meeting.
So fox news had this on there twitter account today so i posted a link to Medizone.
Antiseptic invented in 1912 could battle viruses and superbugs http://fxn.ws/2gxlxxz
Look at these crazy trading numbers 0.153964
How come there are no alerts at the top of the board
This is great news long time coming for us.
Buy out no but i do think Marshall is going to step down. The calls from some share holders has most likely put pressure on who ever has been funding this and the threat of a shareholder meeting may have been enough for them.
Sounds to me like some one or some company is going to take this over.
Is this not the same thing that happened back in the Aids days. but with the FDA. Seems like they have pissed off a lot of bureaucrats then, that this keeps happening to this company.
I hate to say this but as we keep giving these shares out at some time MZEI is going to have to Reverse split the stock or we will be to diluted if we are not there already.
Got this Email today.
http://www.medizoneint.com/2015/06/30/asepticsure-research-and-awards/
Esposito David Bought a million shares today at .05 i wonder what mile stone had to be met to get them EPA approval ?
I hope you see it Go
I got it in an E-mail today
AsepticSure®
Progress Update
June 1, 2015
Medizone International appears on the cusp of strong commercial breakthroughs. The superior efficacy of the AsepticSure process backed by its unassailable science is no longer in question. AsepticSure has proven to be the only hospital disinfection, cleaning technology that repeatedly eliminates all known pathogens in the space treated, demonstrating in-hospital the ability to break the hospital acquired infection (HAI) reinfection cycle. At the provincial level in Canada the medical community is starting to take serious notice.
New Canadian Initiatives:
A Provincial Ministry of Health in Canada has recently requested a demonstration of AsepticSure at two of its major hospitals in two different cities. It should be noted that these are not trials, but demonstrations of the systems operation. Dr. Shannon, along with our Canadian distributor Wood-Wyant, will be conducting these demonstrations. It has been communicated to Dr. Shannon from this Provincial Ministry of Health's office that, "their search for a hospital disinfection technology suitable for adoption by the Province had been narrowed down to only one, AsepticSure."
This is understandable in that recent peer-reviewed scientific literature has made it abundantly clear that the claims made for the disinfection capabilities of the ultra violet light systems have been grossly overstated. Straight hydrogen peroxide technologies have proven far more time consuming, toxic to the environment, and far less efficacious. Only AsepticSure has continued to demonstrate its 6-log efficacy while fitting nicely into normal hospital workflows. It is absolutely "green" in the sense that all medical equipment remains in the room during cleaning and the 100% disinfected space is then available for immediate occupancy the moment the door is opened following the disinfection cycle.
The Provincial Ministry's purchasing agent is now playing a leading role in setting up these demonstrations, which are expected to take place in July following the Canadian National Infection Prevention and Control Conference in Victoria, BC. (This medical conference takes place June 14th through June 17, 2015.) At the conference, Queen's University Professor Dr. Dick Zoutman, will be giving two talks and poster presentations on AsepticSure's applications. These will be titled respectively, "Time, Cost Efficiency and Effectiveness of a Novel ozone-Hydrogen Peroxide Disinfection System (ARDS) During a Clostridium difficile Outbreak on an Acute Medical Unit" and "High Level Disinfection Effectiveness of a Novel Ozone-Hydrogen Peroxide Vapour Automated Room Disinfection System (ARDS) Against Non-Enveloped and Enveloped Viruses."
Activities in Preparation for US Market Entry:
Preliminary planning has recently been initiated for demonstration of efficacy trials at two US hospitals. The intent of these trials is to replicate what has been achieved at Quinte Health Care's Bellville General and Trenton Memorial Hospitals, breaking the isolation room re-infection cycle and stopping new HAI's in their tracks. These trials will be conducted by a leading hospital contract cleaning service company working with the hospitals quality assurance personnel.
Assuming a successful trial outcome with results unequivocally demonstrating a greater than 6-log (>99.9999%) disinfection capability in all critical spaces (which essentially resets infection prone problem rooms as the safest rooms in the hospital), adoption of AsepticSure as their technology of choice is a distinct possibility. Until start dates are established and announced by the contractor, we will not be releasing any additional information.
This update may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor Relations
T: (415) 331-0202
E:j.pentony@medizoneint.com
Gary Hanauer, Media Contact
T: (510) 686-1238
E:GarHan@aol.com
For more information, visit: http://www.medizoneint.com
Email: operations@medizoneint.com
I will ask this again is it possible that ASEPTICSURE is to good ?
Will it lead more to renting then buying the machine?
Quick read and we are stuck in the hands of the EPA
The Halo Disinfection System from Sanosil International , in conjunction with a comprehensive cleaning,
Pennsylvania Hospital used the fogger to alleviate the spread of C. difficile, a bacteria that causes diarrhea and increasingly spreads in hospital settings, that had been spread person-to-person through contact with bedside computers. The fogger reduced the spread of new cases 66 percent from 4.9 new cases per 10,000 patient days to 1.65.
MRSA) outbreak using AsepticSure® in June 2013 has now gone an entire year without a new case of MRSAThis is highly significant in that each of the rooms that had contained a MRSA patient was only cleaned a single time following patient discharge. Previously, the hospital reported averaging one to two new MRSA infections per month on the ward.
The Delaware company still did not stop 100% We have now gone 1 YEAR with out a new case.
Also, Dr. Dick Zoutman, Chief of Staff of Belleville General Hospital in Belleville, Ontario, Canada has now reported the ward of his hospital that was cleared of a Methicillin-resistant Staphylococcus aureus (MRSA) outbreak using AsepticSure® in June 2013 has now gone an entire year without a new case of MRSA. This is highly significant in that each of the rooms that had contained a MRSA patient was only cleaned a single time following patient discharge. Previously, the hospital reported averaging one to two new MRSA infections per month on the ward.
In August 2014, Medizone completed a viral research study in collaboration with the Viral Vector Production Team, Human Health Therapeutics, National Research Council of Canada (“NRC”). Following these trials the NRC has confirmed AsepticSure® has demonstrated 100% kill of both Adenovirus and the internationally recognized study surrogate for MERS Coronavirus, in a full-scale room setting.
By destroying both of these viruses, one a non-enveloped virus and the second an enveloped Coronavirus, our understanding of the biological limits for AsepticSure® has been expanded dramatically and so has the range of medical applications. AsepticSure® has demonstrated the ability to eliminate all bacterial pathogens it has been tested against, including the most difficult to kill spore formers such as Clostidium difficile and the study surrogates for Anthrax, Bacillus atropheus and Bacillus subtilis. The system is proving fully effective against viral pathogens as well.
Medizone’s scientists, along with the viral researchers at the NRC, have confirmed that given the success with the viral pathogens tested, AsepticSure® should not have any difficulty killing Ebola as well, as it is considered a less difficult virus to kill than Adenovirus or MERS Coronavirus. There is no known study surrogate for Ebola. We have not yet performed any tests or clinical trials involving Ebola.
The new findings described above should have intriguing implications for the management of new deadly outbreaks world-wide. Experts in this field have known for years that bacterial spores and non-enveloped viruses are at the top of the biological resistance list for pathogens and we have extensive data confirming that AsepticSure® can achieve 100% kill of these pathogens at very high concentrations. What is most exciting about these recent findings is that highly lethal viruses such as Ebola should be extremely susceptible to AsepticSure® disinfection, which may therefore see AsepticSure emerge as a vital component in global efforts to control these new deadly outbreaks.
Following our public reporting of this viral work we were contacted by Medecins San Frontieres (Doctors without Borders). In conjunction with the company Design Shelter, we demonstrated the effectiveness of AsepticSure® in a portable field hospital setting. Attending the demonstration along with representatives of Medecins San Frontieres were members of the Canadian Red Cross and Canadian Military. Following that successful demonstration, we were invited to work with representatives of Design Shelter and Medecins San Frontieres to produce a prototype design for a 30 to 40 bed, expandable field hospital equipped with AsepticSure® that could be deployed in West Africa. The design was carefully considered to assure 100% separation between the Ebola treatment area of the compound and the Ebola evaluation area. High level controls must be in place for this type of design to assure patients being evaluated that may not have Ebola are not exposed during the evaluation process. The requested design was completed and has been submitted for consideration to Medecins San Frontieres.
NSD you are missing the point there times when a company has to put aside profit for the greater good of humanity this is what he is talking about.. Every thing they bring will be either free or at cost.
I think you are taking his words out of context. He is not saying that MZEI dose not want to make a profit as an over all company but in the case of Ebola they are willing to not make a profit for the better good of this world Crisis. I have no problem with it in this case if it gets our product out there.
Just maybe this will get the EPA off there collective butts and get moving on us. Also lets not for get MZEI in the early years was working on blood purification could MZEI be possibly working on this again for EBOLA ?
for Medizone as we are rapidly approaching an exciting time that should soon see dramatic growth and demand for our AsepticSure® hospital disinfection systems.
Green how is sending a machine there going to stop this.
Good Morning the only problem it is spread by contact. Body fluids.
http://www.ask.com/wiki/Ebola_virus_disease